Huntington’s Disease (HD): A Rare and Deadly Disorder
uniQure is developing a gene therapy for Huntington’s disease (HD), a rare, fatal, neurodegenerative genetic disorder that affects motor function and leads to behavioral symptoms and cognitive decline in young adults, resulting in total physical and mental deterioration. HD is caused by the expansion of CAG trinucleotide in exon 1 of a multifunctional gene coding for protein called huntingtin.
According to the EMA, Huntington’s disease affects approximately 70,000 people in the U.S. and Europe, making this one of the largest clinical unmet needs in the rare disease field. Despite the clear etiology of the disease, there are no therapies available to treat the disease, delay its onset, or slow the progression of a patient’s decline.
uniQure’s AMT-130 for Huntington’s Disease
Our gene therapy product candidate AMT-130 consists of an AAV5 vector carrying an artificial micro-RNA specifically tailored to silence the huntingtin gene, leveraging our proprietary miQURE™ silencing technology. The therapeutic goal is to inhibit the production of the mutant protein (mHTT). Using AAV vectors to deliver micro-RNAs directly to the brain for non-selective knockdown of the huntingtin gene represents a highly innovative and promising approach to treating Huntington’s disease.
AMT-130 administration animated video
A Differentiated Gene Therapy Approach
uniQure’s gene therapy candidate for Huntington’s disease is differentiated in that:
AMT-130 targets the deep brain structures known for the disease pathology onset.
AMT-130 silences mutant huntingtin protein at levels not demonstrated in other studies.
AMT-130 targets the accumulation of the exon 1 HTT fragment, the most toxic source of abnormal protein aggregation in Huntington’s disease.
We are very encouraged by the significant reductions in mutant huntingtin protein, and believe that knock-down of this magnitude has the potential to significantly alter the course of the disease.
Orphan Drug Designation Granted in the U.S. and Europe
The U.S. Food and Drug Administration has granted orphan drug designation for AMT-130 in Huntington’s disease and AMT-130 has received an Orphan Medicinal Product Designation (OMPD) from the European Medicines Agency for the same indication, making it the first investigational AAV gene therapy in Huntington’s disease to receive such designation. In April 2019, we announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AMT‑130, underscoring the high unmet medical need for patients suffering from Huntington’s disease.
Phase I/II Clinical Trial of AMT-130
The U.S. Phase I/II clinical trial of AMT-130 is exploring the safety, tolerability, and efficacy signals in 26 total patients with early manifest Huntington’s disease split into a 10 patient, low-dose cohort followed by a 16 patient, high-dose cohort; patients are randomized to treatment with AMT-130 or an imitation (sham) surgery. The multi-center trial consists of a blinded 12-month core study period followed by unblinded long-term follow-up for five years. A total of 16 patients in the clinical trial were randomized to treatment and received a single administration of AMT-130 through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen). An additional four control patients in the high-dose cohort crossed over to treatment.
The European, open-label Phase Ib/II study of AMT-130 has now enrolled 12 of 15 total patients with early manifest Huntington’s disease across two dose cohorts. The low-dose cohort of six patients has completed enrollment with the remaining high-dose cohort expected to complete enrollment in mid-2023. Together with the U.S. study, the European study is intended to establish safety, proof of concept, and the optimal dose of AMT-130 to take forward into Phase III development or into a confirmatory study should an accelerated registration pathway be feasible.
In June 2023, we announced promising interim data, including up to 24 months of follow-up, from 26 patients enrolled in the ongoing U.S. trial, that show early signs of a potential clinical benefit of AMT-130 and supportive trends in neurofilament light chain (NfL), a key marker of neuronal damage. AMT-130 continues to be generally well-tolerated with a manageable safety profile at both doses. Importantly, both doses show preliminary evidence of clinical and functional benefits, including favorable trends in Total Motor Score, Total Functional Capacity and the composite Unified Huntington’s Disease Rating Scale compared to natural history.
Patients treated with either dose of AMT-130 appear to have largely preserved function and are trending favorably to natural disease course at up to 24 months. We believe these interim results provide early hope for patients suffering from this devastating disease.
In February 2019, uniQure presented 12-month follow-up data in a Huntington’s disease minipig model, the largest available animal model for the disease. The data demonstrated that a single administration of AMT-130 resulted in a dose-dependent and sustained reduction of mutant huntingtin protein (mHTT) in the deep structures of the brain – including the striatum and the putamen, where Huntington’s disease is known to manifest, and the cortex. Once administered, AMT-130 was observed to spread to the cerebral cortex and lowered mHTT in the frontal areas of the brain that show neuropathological changes later in the course of the disease, providing evidence that AMT-130 spread from the injection sites to the cerebral cortex.
Preclinical studies using a non-invasive technique, Magnetic Resonance Spectroscopy (MRS), demonstrate that in addition to significant knock-down of mHTT, a single administration of AMT-130 also leads to an improvement in brain cell function, a reversal in HD neuropathology, and a partial reversal of volume loss in a key brain area involved in memory, called the hippocampus.